Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Orteronel Maintenance Therapy in Patients With Metastatic Castration Resistant Prostate Cancer and Non-progressive Disease After First-line Docetaxel Therapy

This study has suspended participant recruitment.
(Due to decision of Pharmaceuticals to discontinue the development support on orteronel (TAK-700) in prostate cancer.)
Sponsor:
Information provided by (Responsible Party):
Swiss Group for Clinical Cancer Research
ClinicalTrials.gov Identifier:
NCT01707966
First received: September 13, 2012
Last updated: September 2, 2014
Last verified: September 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has suspended participant recruitment.
  Estimated Study Completion Date: December 2020
  Estimated Primary Completion Date: August 2016 (Final data collection date for primary outcome measure)